

DAFTAR PUSTAKA

1. Levin L, Nilsson S, Hoeve JV, et al. Lens. In: Adler's Physiology of The Eye. 11th edition. Mosby Elsevier; 2011. p. 131-162.
2. Skuta GL, Cantor LB, Weiss JS. Anatomy. In: Lens and Cataract. San Fransisco: American Academy of Ophthalmology; 2019-2020. p. 9-13.
3. National Eye Institute. Cataract Data and Statistics. National Eye Institute; 2019. Available from: <https://www.nei.nih.gov>.
4. Thylefors B, Negrel A, Pararajasegaram R, Dadzie KY. Global Data on Blindness. *Bulletin of the World Health Organization*. 2015; 73(1): p. 115-21.
5. Departemen Kesehatan. Katarak Penyebab Utama Kebutaan di Indonesia. 2017. Available from: <http://www.depkes.go.id/article/review/17100400003/katarak-penyebab-utama-kebutaan>
6. Pusat Data dan Informasi Kementerian Kesehatan Republik Indonesia. 2018. p.1-11.
7. Kementerian Kesehatan Republik Indonesia. Badan Penelitian dan Pengembangan Kesehatan (Balitbangkes). Hasil Utama Riset Kesehatan Dasar. 2018. p: 78.
8. Javadi MA, Ghanavati SZ. Cataract in Diabetic Patients: A Review Article. In: *Journal of Ophthalmic and Vision Research*. 2010. p. 52-65.
9. Rotimi C, Daniel H, Zhou J, et al. Prevalence and Determinant of Diabetic Retinopathy and Cataracts in West African Type 2 Diabetes Patients. Washington CD: College of Medicine Howard University. 2015. p. 79-87.
10. Pollreisz A, Ursula SE. Diabetic Cataract-Pathogenesis, Epidemiology, and Treatment. Hindawi Publishing Corporation *Journal of Ophthalmology*. 2010. p. 1-8.
11. Lang GK, Amann J, Gareis O, et al. *Ophthalmology a Short Textbook*. New York: Thieme Stuttgart; 2000. p. 237-239.
12. Olafsdittir E, Dan KGA, Einar S. The Prevalence of Cataract in a Population With and Without Type 2 Diabetes Mellitus. *Acta Ophthalmologica* 2012. p: 334-340.
13. Kyselova Z, Stefek M, Bauer V. Pharmacological Prevention of Diabetic Cataract. *Journal of Diabetes and Its Complication*. 2014. p. 129-140.
14. Khurana AK, Khurana I. The Crystalline Lens. In: *Anatomy and Physiology of Eye 2nd Edition*. CBS Publishers & Distributors. 2008. p. 85-121.
15. Patil MA, Palla S, Uday KP, et al. Evaluation of Neonatal Streptozotocin Induced Diabetic Rat Model for the Development of Cataract. *Oxidative Medicine and Cellular Longevity* 2014. p. 1-11.
16. Gong X, Qiuyan Z, Shuhua T. Inhibitory Effect of r-Hirudin Variant III on Streptozotocin-Induced Diabetic Cataracts in Rats. Hindawi Publishing Corporation *The Scientific World Journal*. 2013. p. 1-8.
17. Chung SSM, Eric CMH, Karen SL. Contribution of Polyol Pathway to Diabetes-Induced Oxidative Stress. *Journal of the American Society of Nephrology*. 2009. p. 233-236.
18. Lykkesfeldt J. Malondialdehyde as Biomarker of Oxidative Damage to Lipids caused by Smoking. *Clinica Chimica Acta* 2010; 380: 50-8.
19. Singh Z, Karthigesu IP, Singh P, Kaur R. Use of Malondialdehyde as a Biomarker for Assessing Oxidative Stress in Different Disease Pathologies: a Review. *Iranian Journal Public Health*. 2014;43(3):7-16.
20. Jain AK, Gideon L, Marlyn L, et al. Effect of High Glucose Levels on Protein Oxidation in Cultured Lens Cells, and in Crystalline and Albumin Solution and Its Inhibition by Vitamin B6, and N-acetylcysteine: Its Possible Relevance to Cataract Formation in Diabetes. *Free Radical Biology and Medicine* Volume 33 No 12. 2012. p. 1615-1621.

21. International Application Published Under the Patent Cooperation Treaty. Use of N-acetylcysteine in the Treatment of Disease and Injury. World Intellectual Property Organization. 2013. p. 1-55.
22. Andrade KQ, Fabiana AM, John MS, et al. Oxidative Stress and Inflammation in Hepatic Diseases: Therapeutic Possibilities of N-Acetylcysteine. International Journal of Molecular Sciences. 2015. p. 30269-30308.
23. Maddirala SKY, Shakila T, Nuran E. Effects of N-acetylcysteine (NAC) Eye Drops on Acetaminophen-Induced Cataracts in C57NL/6 Mice. J Free Rad Biomed. 2013. p. 710-714.
24. Nahdi AM, Annie J, Haider R. Cytoprotective Effects of N-Acetylcysteine on Streptozotocin-Induced Oxidative Stress and Apoptosis in RIN-5F Pancreatic β -Cells. Cell Physiol Biochem 2018. p. 201-216.
25. Zhang S, Feiyan C, Hong Y, et al. Effects of N-Acetylcysteine and Glutathione Ethyl Ester Drops on Streptozotocin-Induced Diabetic Cataract in Rats. Molecular Vision. 2010. p. 862-870.
26. Klinworth GK, Garner A. Structure and Biochemistry of the Lens. In : Pathobiology of Ocular Disease 3rd Edition. New York: Informa Healthcare. 2008. p. 445-464
27. Jogi R. The Lens. In : Basic Ophthalmology 4th Edition. Jaypee Brothers Medical Publishers (P) LTD. New Delhi. 2009. p. 205-210.
28. Yanoff M, Duker JS. Basic Science of the Lens. In : Ophthalmology 4th Edition. Elsevier Saunders. 2014. p. 329-343.
29. West MJ, Bowman S. Animal Models of Cataracts. Essentials in Ophthalmology. Switzerland. Springer. 2016. p. 11-29.
30. Lim JC, Irene V, Renita MM, Paul JD. Animal Models in Cataract Research. Animal Models for the Study of Human Disease. Elsevier 2017. p. 103-116.
31. Onodera H, Sasaki S, Otake S. General Considerations in Ocular Toxicity Risk Assessment from the Toxicologist's Viewpoints. The Journal of Toxicological Sciences Vol 40 No 3. 2015. p. 295-307.
32. Dubielzig D. Ocular Anatomy and Variations in Laboratory Animals: Rodent, Rabbit, Primate, and Dog. Comparative Ocular Pathology Laboratory of Wisconsin. 2010. p. 1-33.
33. Khorsand M, Masoumeh A, Sahab S, et al. Melatonin Reduces Cataract Formation and Aldose Reductase Activity in Lenses of Streptozotocin-Induced Diabetic Rat. Iran J Med Sci 2016; Voume 41 No 4. p. 305-313.
34. Suryanarayana P, Megha S, Tirwalluru M, et al. Curcumin and Turmeric Delay Streptozotocin-Induced Diabetic Cataract in Rats. Investigative Ophthalmology and Visual Science 2015; Volume 46, No 6. p. 2092-2099.
35. Ayala A, F. Muñoz M, Argüelles S. Lipid Peroxidation: Production, Metabolism, and Signaling Mechanisms of Malondialdehyde and 4-Hydroxy-2-Nonenal. Hindawi Publishing Corporation. 2014. p. 1-31.
36. Oduntan O, Mashige K. A Review of the Role of Oxidative Stress in the Pathogenesis of Eye Diseases. The South African Optometrist. 2011; 70(4): 191-9.
37. Halliwell B, Gutteridge JMC. Free Radicals in Biology and Medicine 4th Edition. New York: Oxford. 2009. p. 317-331.
38. Droge W. Free Radicals in the Physiological Control of Cell Function. Physiol Rev. 2012. p. 47-95.
39. Pham-Huy LA, He H, Pham-Huy C. Free Radicals, Antioxidants in Disease and Health. International Journal of Biomedical Science. 2010. p. 89-96.
40. Made I. Bahan Ajar Antioksidan. Program Pascasarjana Universitas Udayana. 2016. P. 1-54.

41. Yan H, Harding JJ. Glycation Induced Activation and Loss of Antigenicity of Catalase and Superoxide Dismutase. *Biochem J* 2010. p. 599-605.
42. Turk Z, Misur I. Temporal Association between Lens Protein Glycation and Cataract Development in Diabetic Rats. *Acta Diabetol* 2011. p. 49-54.
43. Novriah D. Kerusakan Sel β Pankreas Akibat Induksi Streptozotocin: Tinjauan Patologi Eksperimental. *Mandala of Health Volume 3 (2)* 2018. p. 46-51.
44. Itoh N, Imagawa A, Hanafusa T, Waguri M, Yamamoto K, Iwahashi H, et al. Requirement of Fas for the Development of Autoimmune Diabetes in Non Obese Diabetic Mice. *J Exp Med* 2010. p. 613-18.
45. Lgssiar A, Hassan M, Schott-Ohly P, Friesen N, Nicoletti F, Trepicchio WL, et al. Interleukin-11 Inhibits NF κ B and AP-1 Activation in Islets and Prevents Diabetes Induced with Streptozotocin in Mice. *Exp Biol Med* 2014; 229: 425-36.
46. Gille L, Schott OP, Friesen N, Schulteim WS, Udilova N, Nohl H, et al. Generation of Hydroxyl Radicals Mediated by Streptozotocin in Pancreatic Islets of Mice in Vitro. *Pharmacol Toxicol* 2012; 90: 317-26.
47. Simon OR, West ME. Unstable Diabetic State Produced by a Small Dose of Streptozotocin in Rats. *West Indian Med J* 2012; 41: 146-49.
48. Rossini AA, Like AA, Chick WL, Appel MC, Cahill GF. Studies of Streptozotocin-Induced Insulinitis. *Mandala of Health. Vol 3 (2)* 2010. p. 339-43.
49. Odetti P, Carlo P, Nicola T, et al. Comparative Trial of N-acetylcysteine, Taurine, and Oxerutin on Skin and Kidney Damage in Long-Term Experimental Diabetes. *Diabetes Vol 52* 2013. p. 499-505.
50. Acer S, Gokhan P, Vural K, et al. Oxidative Stress of Crystalline Lens in Rat Menopausal Model. *Arq Bras Oftalmol* 2016; 79(4): 222-5.
51. Firdaus, Rimbawan, Marliyati SA, et al. Model Tikus Diabetes yang Diinduksi Streptozotocin untuk Pendekatan Penelitian Diabetes Mellitus Gestasional. *Jurnal MKMI Volume 12 No 1*, 2016. p. 29-34.
52. Yadav A, Kumari R, Yadav A, Mishra JP, Srivastva S, Prabha S. Antioxidants and Its Functions in Human Body - A Review. *Research in Environment and Life Sciences*. 2016;9(11):1328-30.
53. Werdhasari A. Peran Antioksidan Bagi Kesehatan. *Jurnal Biotek Medisiana Indonesia Volume 3.2*; 2014. p. 59-68.
54. Marwanta S. Pengaruh N-asetilsistein Oral terhadap Penurunan Kadar TNF- α dan Prokalsitonin pada Pasien Penyakit Ginjal Kronis Stadium V yang Menjalani CAPD di RSUD Dr. Moewardi. Program Pasca Sarjana Universitas Sebelas Maret Surakarta. 2012. p: 1-114.
55. Lesniewska DM, Piotr S. N-acetylcysteine as an Anti-oxidant and Anti-inflammatory Drug and Its Some Clinical Applications. *Central European Journal of Immunology* 2012; 37 (1).
56. Messina M, Harminder SD. Early Results on the Use of Chitosan-N-acetylcysteine (Lacrimera) in the Management of Dry Eye Disease of Varied Etiology. *Int Ophthalmol* 2019. p. 693–696
57. Kamalakkannan N, Rukkumani R, Aruna K, et al. Protective Effect of N-acetylcysteine in Carbon Tetrachloride Induced Hepetotoxixity in Rats. *Iranian Journal of Pharmacology and Therapeutic*. 2005. p. 118-123.
58. Williamson J, Malcolm D, Forrester MH, et al. Management of the Dry Eye in Sjogren's Syndrome. *Brit Journal Ophthalmology* 2014. p. 798-805.
59. Salman IA, Sedat A, Ugur M, et al. Efficacy of Topical N-acetylcysteine in the Treatment of Meibomian Gland Dysfunction. *Journal of Ocular Pharmacology and Therapeutics Volume 26, No 4*, 2010. p. 329-333

60. Maddirala Y, Shakila T, Humeyra K, Nuran E. Prevention and Reversal of Selenite-Induced Cataracts by N-Acetylcysteine in Wistar Rats. *BMC Ophthalmology*. 2017. p. 17-54.
61. Rathbun WB, Ann MH, Jonathan FC, Herbert TN. Prevention of Acetaminophen and Naphthalene-Induced Cataract and Glutathione Loss by CySSME. *Invest Ophthalmol Vis Sci*. 2010. p. 923-929.
62. Selin JZ. Oxidative Stress and Age Related Cataract. Stockholm: Karolinska Institute; 2015. p. 1-76.
63. Vasudevan S, Abraham A. Age Related or Senile Cataract: Pathology, Mechanism and Management. *Journal of Clinical Ophthalmology*. 2016;3(2):1067-77.
64. Ates N, Yildirim O, Tamer L. Plasma Catalase Activity and MDA Level in Patients with Cataract. 2004. p. 1-5.
65. Hosokawa M, Wanda D, Bernard T. Differential Sensitivity of GLUT1 and GLUT2-Expressing β Cells to Streptozotocin. *Biochemical and Biophysical Research Communications*. 2012;289:1114-1117.
66. Ai Jing, Ning W, Mei Y. Development of Wistar Rat Model of Insulin Resistance. 2015;11(24):3675-3679.
67. Ramdhave AS, Ojha S, Nandave M. Energy Intake Correlates with the Levels of Fatty Acid Synthase and Insulin-Like Growth Factor-1 in Male and Female C57BL/6Mice. 2017;9(3):830-844.
68. Munshi RP, Samidha GJ, Bhagyeshri NR. Development of an Experimental Diet Model in Rats to Study Hyperlipidemia and Insulin Resistance and Markers for Coronary Heart Disease. *Indian Journal of Pharmacology Issue 3*. 2014;46:270-6.
69. Anita AU, Alina G, Paul S. Rapid Insertion of GLUT2 into the Rat Jejunal Brush-Border Membrane Promoted by Glucagon-like Peptide 2. *Biochem Journal*. 2012; 367: 247-254.
70. Saputra NT, Nyoman S. Agen Diabetogenik Streptozotocin untuk Membuat Tikus Putih Jantan Diabetes Mellitus. *Buletin Veteriner Udayana Volume 10 No. 2*. 2018. p 116-121.
71. Cohen SE, Tseng YH, Michael MD. Effects of Insulin-Sensitising Agents in Mice with Hepatic Insulin Resistance. *Diabetologia*. 2014; 47: 407-411.
72. Skuta GL, Cantor LB, Cioffi AG. Cornea. In: *Fundamental and Principles of Ophthalmology*. American Academy of Ophthalmology. Basic and Clinical Science Course. Section 2. Singapore: FSC; 2020-2021. p 223-227.
73. Raj VK, Rupa M, Monika M. Ocular Drug Delivery System: Challenges and Approaches. *International Journal of Applied Pharmaceutics Volume 12, Issue 5*. 2020. p 49-57.